| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $86K | — | — |
| Cost of Revenue | $279K | — | — |
| R&D Expense | $11.4M | -5.7% | +47.9% |
| SG&A Expense | $8.8M | +7.3% | +47.5% |
| Operating Income | -$20.4M | -0.5% | -49.2% |
| Net Income | -$19.4M | -1.1% | -52.9% |
| EPS (Basic) | -$0.29 | -3.6% |
| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| Cash & Equivalents | $95.2M | -10.5% | +20.5% |
| Accounts Receivable | $15K | — | — |
| Inventory | $57K | +11.8% | — |
| Current Assets | $97.2M | -10.2% | +20.8% |
| Total Assets | $108.8M | -9.6% | +16.9% |
| Current Liabilities | $9.7M |
| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| Operating Cash Flow | -$39.4M | — | — |
| Capital Expenditures | $210K | — | — |
| Investing Cash Flow | -$230K | — | — |
| Financing Cash Flow | $16.8M | — | — |
| Free Cash Flow | -$39.6M | — | — |
| -38.1% |
| +8.0% |
| +43.9% |
| Total Liabilities | $16.1M | +1.9% | +15.5% |
| Stockholders' Equity | $92.7M | -11.3% | +17.1% |